or Try an Advanced Search...

    Technical Analysis for PYXS - Pyxis Oncology, Inc.

    Grade Last Price % Change Price Change
    C 3.82 -8.17% -0.34
    PYXS closed down 8.17 percent on Wednesday, November 20, 2024, on 7.65 times normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Down
    Historical PYXS trend table...
    Date Alert Name Type % Chg
    Fell Below 20 DMA Bearish 0.00%
    Fell Below 200 DMA Bearish 0.00%
    Volume Surge Other 0.00%
    Outside Day Range Expansion 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Up Strength 0.00%
    MACD Bearish Signal Line Cross Bearish -8.17%
    20 DMA Support Bullish -8.17%
    200 DMA Support Bullish -8.17%
    Calm After Storm Range Contraction -8.17%
    Older End-of-Day Signals for PYXS ...

       Recent Intraday Alerts

    Alert Time
    Down 1 ATR about 17 hours ago
    Outside Day about 18 hours ago
    Down 5% about 18 hours ago
    Fell Below Previous Day's Low about 18 hours ago
    Fell Below 20 DMA about 19 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    PYXS Chart by TradingView
    Basic chart:

    Profile

    Pyxis Oncology, Inc., a preclinical stage biotechnology company, engages in the development of antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies to treat cancers. Its preclinical products pipeline includes PYX-201, a site-specific investigational ADC targeting onco-fetal fibronectin extradomain-B for the treatment of non-small cell lung cancer; PYX-202, a site-specific investigational ADC targeting delta like non-canonical notch ligand 1 to treat small cell lung cancer, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational site-specific ADC targeting CD123 for the treatment of acute myeloid leukemia and other blood cancers. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Cancer Clinical Medicine Immunology Solid Tumors Immunotherapy Cancer Treatment Monoclonal Antibody Acute Myeloid Leukemia Immunotherapies Non Small Cell Lung Cancer Antineoplastic Drugs Small Cell Lung Cancer Antibody Drug Conjugate Treatment Of Acute Myeloid Leukemia Blood Cancers Soft Tissue Sarcoma Treatment Of Non Small Cell Lung Cancer

    Is PYXS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 20 Pyxis Oncology plummets 38% on preliminary phase 1 data for cancer asset
    Nov 20 Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
    Nov 12 Pyxis Oncology GAAP EPS of -$0.35 misses by $0.04
    Nov 12 Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024
    Nov 11 Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201
    Sep 13 Moment Of Truth Approaches For Pyxis Oncology
    Aug 29 Pyxis Oncology to Participate in Two Upcoming Investor Conferences
    Aug 15 Pyxis Oncology GAAP EPS of -$0.29
    Aug 14 Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
    Aug 8 Pyxis Oncology draws Buy at Stifel on lead asset
    See more PYXS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 6.85
    52 Week Low 1.35
    Average Volume 694,766
    200-Day Moving Average 4.06
    50-Day Moving Average 3.71
    20-Day Moving Average 4.02
    10-Day Moving Average 4.25
    Average True Range 0.32
    RSI (14) 46.81
    ADX 33.09
    +DI 28.13
    -DI 19.85
    Chandelier Exit (Long, 3 ATRs) 4.44
    Chandelier Exit (Short, 3 ATRs) 4.34
    Upper Bollinger Bands 4.65
    Lower Bollinger Band 3.39
    Percent B (%b) 0.34
    BandWidth 31.20
    MACD Line 0.14
    MACD Signal Line 0.18
    MACD Histogram -0.0339
    Fundamentals Value
    Market Cap 169.31 Million
    Num Shares 44.3 Million
    EPS -2.56
    Price-to-Earnings (P/E) Ratio -1.49
    Price-to-Sales 0.00
    Price-to-Book 1.19
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.59
    Resistance 3 (R3) 4.66 4.49 4.46
    Resistance 2 (R2) 4.49 4.29 4.45 4.41
    Resistance 1 (R1) 4.15 4.17 4.07 4.08 4.37
    Pivot Point 3.98 3.98 3.93 3.94 3.98
    Support 1 (S1) 3.64 3.78 3.56 3.57 3.27
    Support 2 (S2) 3.47 3.66 3.43 3.23
    Support 3 (S3) 3.13 3.47 3.18
    Support 4 (S4) 3.06